Involvement of Nitric Oxide in Nickel-Induced Hyperglycemia in Rats

• Published in: Nitric oxide 2000-04, Vol.4 (2), p.129-138
• Main Authors: Gupta, Sanjay, Ahmad, Nihal, Husain, Mirza M., Srivastava, Ramesh C.
• Format: Article
• Language: English
• Subjects: Adrenal Glands - metabolism; Animals; Blood Glucose - drug effects; Blood Glucose - metabolism; Brain - metabolism; Calcium - metabolism; Cyclic GMP - metabolism; cyclic-GMP; Drug Interactions; Enzyme Inhibitors - pharmacology; hyperglycemia; Hyperglycemia - chemically induced; Hyperglycemia - enzymology; Hyperglycemia - metabolism; Immunoblotting; Male; NG-monomethyl-[formula omitted]-arginine; NG-Nitroarginine Methyl Ester - pharmacology; nickel; Nickel - pharmacokinetics; Nickel - pharmacology; nitric oxide; Nitric Oxide - physiology; Nitric Oxide Synthase - biosynthesis; Nitric Oxide Synthase - metabolism; Pancreas - metabolism; Rats
• ISSN: 1089-8603; 1089-8611
• DOI: 10.1006/niox.2000.0278

Nitric oxide is an important bioactive signaling molecule that mediates a variety of normal physiological functions which, if altered, could contribute to the genesis of many pathological conditions, including diabetes. In the present study we have shown the involvement of NO in nickel-induced hyperglycemia in male albino rats. Administration of nickel chloride (25 to 100 μmol/kg; ip) to overnight-fasted rats resulted in significant dose and time-dependent increase in plasma glucose, attaining maximum level at 1 h posttreatment and thereafter decreasing to normal levels by 4 h. The involvement of NO in nickel-induced hyperglycemia was evident by the observation that pretreatment of rats with NG-monomethyl-l-arginine (10 to 50 μmol/kg; ip), an inhibitor of nitric oxide synthase (NOS), significantly attenuated the nickel-mediated increase in the plasma glucose levels in a dose-dependent fashion. The activity of Ca2+-dependent NOS (constitutive form, c-NOS) was found to be significantly elevated in adrenals (5.5-fold) and brain (1.4-fold) at 1 and 2 h posttreatment, attaining normal levels by 4 h. In contrast, the activity of c-NOS in pancreas was significantly decreased (2.8-fold) with a concomitant increase (11.6-fold) in inducible NOS (i-NOS) at the same time interval. As observed by immunoblot analysis, a significant increase in i-NOS protein expression in the pancreas was observed at 1 and 2 h posttreatment. This was associated with a significant elevation in cGMP levels in adrenals, brain, and pancreas, possibly via the stimulation of cytosolic guanylate cyclase. This elevation in cGMP was abolished by low concentration of hemoglobin. These effects were associated with the accumulation of nickel in the target tissues. Taken together, our data suggest that nickel causes a significant increase in the levels of (i) cGMP and c-NOS in adrenals and brain and (ii) i-NOS in pancreas. These events may be responsible for modulating the release of insulin from pancreas finally leading to hyperglycemic condition in rats.